Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib with re-induction chemotherapy in pediatric relapsed or refractory FLT3-ITD acute myeloid leukemia
NL-OMON52604Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib in acute myeloid leukemia (AML) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety profile, Dose-limiting toxicities and 2 more. Started Apr 2020; status: recruiting.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON52604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52604.